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Autologous bone marrow mononuclear cell
therapy is safe and promotes amputation-free
survival in patients with critical limb ischemia
Michael P. Murphy, MD,a,b Jeffrey H. Lawson, MD, PhD,c Brian M. Rapp, MD,a
Michael C. Dalsing, MD,a Janet Klein, RN,a Michael G. Wilson, PhD,b Gary D. Hutchins, PhD,e and
Keith L. March, MD, PhD,b,d Indianapolis, Ind; and Durham, NC
Objective: The purpose of this Phase I open label nonrandomized trial was to assess the safety and efficacy of autologous
bone marrow mononuclear cell (ABMNC) therapy in promoting amputation-free survival (AFS) in patients with critical
limb ischemia (CLI).
Methods: Between September 2005 and March 2009, 29 patients (30 limbs), with a median age of 66 years (range, 23-84
years; 14 male, 15 female) with CLI were enrolled. Twenty-one limbs presented with rest pain (RP), six with RP and
ulceration, and three with ulcer only. All patients were not candidates for surgical bypass due to absence of a patent artery
below the knee and/or endovascular approaches to improving perfusion was not possible as determined by an
independent vascular surgeon. Patients were treated with an average dose of 1.7  0.7  109 ABMNC injected
intramuscularly in the index limb distal to the anterior tibial tuberosity. The primary safety end point was accumulation
of serious adverse events, and the primary efficacy end point was AFS at 1 year. Secondary end points at 12 weeks
posttreatment were changes in first toe pressure (FTP), toe-brachial index (TBI), ankle-brachial index (ABI), and
transcutaneous oxygen measurements (TcPO2). Perfusion of the index limb was measured with positron emission
tomography-computed tomography (PET-CT) with intra-arterial infusion of H2O15. RP, using a 10-cm visual analogue
scale, quality of life using the VascuQuol questionnaire, and ulcer healing were assessed at each follow-up interval.
Subpopulations of endothelial progenitor cells were quantified prior to ABMNC administration using immunocyto-
chemistry and fluorescent-activated cell sorting.
Results: There were two serious adverse events; however, there were no procedure-related deaths. Amputation-free
survival at 1 year was 86.3%. There was a significant increase in FTP (10.2 6.2 mmHg; P .02) and TBI (0.10 0.05;
P  .02) and a trend in improvement in ABI (0.08  0.04; P  .73). Perfusion index by PET-CT H2O15 increased by
19.3  3.1, and RP decreased significantly by 2.2  0.6 cm (P  .02). The VascuQol questionnaire demonstrated
significant improvement in quality of life, and three of nine ulcers (33%) healed completely. KDR but not CD34 or
CD133 subpopulations of ABMNC were associated with improvement in limb perfusion.
Conclusion: This Phase I study has demonstrated safety, and the AFS rates suggest efficacy of ABMNC in promoting limb
salvage in “no option” CLI. Based on these results, we plan to test the concept that ABMNCs improve AFS at 1 year in
a Phase III randomized, double-blinded, multicenter trial. ( J Vasc Surg 2011;53:1565-74.)
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doi:10.1016/j.jvs.2011.01.074Critical limb ischemia (CLI) is defined as insufficient
rterial blood flow to maintain tissue viability of the lower
xtremities due to advanced peripheral arterial disease
PAD).1,2 The clinical manifestations consist of rest pain
nd/or tissue necrosis with ulceration and gangrene, all of
hich herald eventual limb loss. The incidence of CLI in
estern societies is approximately 220 new cases per mil-
ion per year, and, with an aging population, persistent rates
f tobacco abuse, and an increase in diabetes, a steady
rowth of the population at risk is expected.2 Revascular-
zation of the ischemic leg with surgical bypass has provided a
ombination of low mortality and exceptional amputation-
ree survival in the treatment of CLI,3,4 and more recently,
ndovascular approaches have demonstrated equivalent
imb salvage efficacy in this challenging patient popula-
ion.5-9 Despite these advances in surgical and endovascular
echniques, approximately 20% to 40% of patients with CLI
ill not be candidates for either of these approaches due to
lack of autogenous vein or extensive atherosclerotic dis-
ase in the tibial and peroneal arteries.10-12 For these
atients, the only remaining alternative for relief of rest pain
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June 20111566 Murphy et aland infection is amputation of the affected extremity. It is
estimated that between 120 and 500 amputations are per-
formed each year per million population, and one-fourth of
all patients who undergo below-knee amputation will fail
rehabilitation and require chronic institutional care or pro-
fessional assistance at home.2,13 Consequently, the median
cost of managing a patient after amputation is estimated to
be almost twice that of successful limb salvage.14 Beyond
the physical disability and financial cost, there is a signifi-
cant emotional toll as well; psychological testing of patients
with CLI shows quality of life indices similar to patients
with terminal malignancy.15,16 Thus, there is a critical need
to develop novel strategies to promote limb salvage in
patients with CLI with no options for conventional revas-
cularization.
Cell mediated angiogenesis was born a decade ago from
the observation that CD34 cells isolated from peripheral
blood had the capacity to differentiate into fully differenti-
ated and functional endothelial cells in culture.17 These
putative stem cells, termed endothelial progenitor cells
(EPC), can also be isolated from bone marrow (BM) and
express the surface markers CD34, CD133, and kinase
insert domain receptor (KDR).17-19 Most importantly,
BM-derived EPCs have been shown to participate in blood
vessel development in preclinical models of hind limb isch-
emia, providing evidence that EPCs may possess therapeu-
tic utility in treating ischemic tissue.19-21 The Therapeutic
Angiogenesis using Cell Transplantation (TACT) study
demonstrated that intramuscular (IM) injection of the
mononuclear fraction of autologous BM (ABMNCs) into
critically ischemic legs increased perfusion with significant
improvement in ankle-brachial indices, transcutaneous ox-
ygen pressures, and rest pain.22 Subsequent to this van-
guard study, there have been multiple Phase I clinical
reports on the efficacy of ABMNCs in improving limb
salvage in patients with CLI23-27; however, currently there
is no pivotal proof of this concept. The primary objective of
this Phase I/II clinical trial was to assess the safety and
efficacy of ABMNC transplantation in promoting amputa-
tion-free survival (AFS) in patients with CLI. We further
provide a novel measure of cell mediated changes in perfu-
sion and an analysis of the impact of ABMNC subpopula-
tions on clinical outcome.
METHODS
A detailed description is available in the Supplemental
Methods section (Appendix, online only).
Patient selection. Based on the adverse events re-
ported in the TACT trial22 and communication with the
authors, we determined that a sample size of 20 patients
completing the 1-year follow-up interval (anticipating a
10%-15% drop-out rate) would provide sufficient data to
assess safety of ABMNC treatment. Recruits were between
the ages of 21 and 85with CLI, defined as symptoms of rest
pain and/or ulceration with an ankle-brachial index (ABI)
0.55 and/or toe brachial index (TBI) 0.40 (Table I).
Enrolled patients had “no options” for reperfusion of the
index limb, defined as absence of a patent artery below the mnee that was continuous to the foot and thus excluding
ypass, and/or endovascular approaches to improving per-
usion were not possible as determined by an independent
ascular surgeon. All patients had to have been offered
mputation as an eventual treatment option prior to enroll-
ent. The TBI was used to include the subset of CLI
atients with lower extremity vasculitic syndromes that
ave profound ischemia of the foot despite patency of the
ibial arteries proximal to the malleoli. Patients were in-
tructed to continue current medical regimens and activity
evels (including exercise regimens) throughout the course
f the study. Any changes in medications and activity levels
ere noted. Patients with wounds were instructed to con-
inue with the regimen used at the time of enrollment or
herapies considered the standard of care for ischemic ul-
eration. The trial protocol and informed consents were
pproved by the Institutional Review Boards of the institu-
ions, and all patients gave written informed consent to
articipate in the study.
Study design. This was an open-label, single dose
rospective study that consisted of two sequential parts: (1)
njection of ABMNCs isolated using conventional Ficoll
ensity centrifugation (FC; 14 patients) and (2) injection
f ABMNCs using the MarrowStim (MS) closed centrifu-
ation system (Biomet Biologics, Warsaw, Ind; 15 patients,
6 limbs).
Safety analysis. Medical records, concomitant medi-
ation use, electrocardiogram (EKG) results, blood chem-
stry and hematology results, vital signs, and physical exam-
nation findings were tabulated and reviewed for evidence
f adverse and serious adverse events at each follow-up visit
t postprocedure day 1, weeks 4, 8, and 12, and at 6 and 12
able I. Inclusion and exclusion criteria
nclusion criteria Exclusion criteria
1-85 years of age History or evidence of malignancya
est pain and /or
ulcerationb
HbA1C 8.5%
BI 0.55, TBI 0.40 Infected wound on the index limbc
nreconstructable arterial
diseased
Renal insufficiency or failuree
on-pregnant women Left ventricular failuref
ompetent to give
consent
Proliferative retinopathy on retinal
examination
Myeloproliferative disorder
History other than squamous or basal cell carcinoma of the skin. Evidence
ased on screening studies established by the American Cancer Society
chest X-ray, mammography, Papanicolaou smear, prostate specific anti-
en).
For those patients with equivalent arterial insufficiency in both legs, the
ost symptomatic with regard to rest pain and tissue loss was designated as
he index limb.
Evidence of fever, purulence, and/or cellulitis of the index limb with an
levated white blood count.
Enrolled patients were not candidates for surgical bypass or endovascular
evascularization as determined by an independent vascular surgeon.
Insufficiency defined as a creatinine2.0, failure as requiring hemodialysis.
Ejection fraction on echocardiography 30%.onths. The safety of ABMNC administration was deter-
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Volume 53, Number 6 Murphy et al 1567mined by estimating the risks of the procedure for major
complications, including death by review of serious adverse
events (SAE) accumulated during the study.
Amputation-free survival. The primary efficacy out-
come was time to above-ankle amputation of the index leg
or death from any cause, whichever occurred first. Viability
of the index limb was determined at each follow-up visit at
weeks 4, 8, 12 and at 6 and 12 months. All cause mortality
was accrued through hospital records and communication
with referring health care providers.
Measures of perfusion. First toe pressure (FTP),
TBI, ABI, and transcutaneous oxygen pressures (TcPO2)
were measured bilaterally at baseline and at weeks 4, 8, and
12. Patients were evaluated for response to therapy by the
parameter (ABI or TBI) by which they were enrolled. For
patients that met both ABI and TBI inclusion criteria,
response to therapy was measured by ABI. Contrast arte-
riography (CA) and magnetic resonance arteriography
(MRA) were performed at baseline and at 12 weeks in four
patients to score neovascularization in the index limb. Both
of these procedures were abandoned due to a lack of
interpretable data and associated risks. An experimental
positron emission tomography based protocol with com-
puted tomography (PET-CT) was developed to directly
quantify perfusion of the limb using radio-labeled water
(H2O
15).28 PET-CT perfusion images were generated by
intra-arterial injection of H2O
15 and then quantifying the
peak tracer uptake level of H2O
15 in both lower extremities
for a period of 120 seconds. A blood perfusion index (BPI)
was calculated as the ratio ofH2O
15 peak tracer uptake level
of the untreated: treated leg. The BPI was measured at
baseline and at 12 weeks in four patients.
Additional efficacy assessments. Rest pain (RP) was
measured with a 10-cm visual analog scale (VAS) at base-
line and each follow-up visit. Patients were instructed to
place a mark on a line from 0 cm (no pain) to 10 cm (worst
pain previously experienced) that would best describe the
level of pain in the index limb during the previous 24 hours
prior to examination. The distance from the 0-cmmark was
then measured and recorded. The Vascular Quality of Life
Questionnaire (VascuQol) was used to assess quality of life
at baseline and at each follow-up visit. The questionnaire
focuses on the domains of pain, symptoms, emotional
well-being, social function, and activity. The responses
were then scored 1 to 7 (all the item scores divided by 25)
for each evaluation. Ulcer status was assessed at each
follow-up interval and compared with baseline. Complete
healing of the index ulcer with re-epithelialization was
considered a successful response to therapy.
Flow cytometric characterization of endothelial
progenitor cell subpopulations. Fluorescent-activated
cell sorting analysis was used to quantify subpopulations of
EPCs in the mononuclear fraction of the BM aspirate of
eight patients. Antibodies for CD34 (a hematopoietic pro-
genitor marker), CD133 (a nonspecific stem cell marker),
and KDR (an endothelial and monocyte surface marker)
were used with techniques described in the Supplemental
Methods Section (Appendix, online only).18 wStatistical analysis. The primary efficacy outcome of
FS at 1 year was assessed using the product-limit estimate.
he four measures of perfusion (FTP, TBI, ABI, and
cPO2) were analyzed by a repeated measures model that
ccounts for possible heterogeneous variances among ob-
ervations obtained on the same patient. Correlations be-
ween measures of perfusion and cell counts were analyzed
y the Pearson product-moment correlation coefficient.
ifferences in EPC subpopulations between groups and
hanges in the 10-cm VAS and in the domains of the
ascuQol were evaluated using the paired t test.
ESULTS
Patient baseline characteristics. Between September
005 andMarch 2009, we enrolled and treated 29 patients
30 limbs; 14 men/15 women) with CLI with a median
ge of 66 years (range, 23-84 years; Table II). Twenty-two
atients (76%) had a previous surgical bypass or endovas-
ular procedure in the index limb. The mean baseline TBI
able II. Characteristics of the study population at
aseline
ariable N (29) %
ge, mean  SE (range) 61.3  12.6 (23-84)
ender
Male 14 48
Female 15 52
ody mass indexa (mean  SE) 25  4
iabetes 6 21
HbA1c (mean, range) 6.6 (5.8-7.6)
obacco use
Active 2 7
Former 17 59
ypertension 15 52
yperlipidemia 18 62
ypercoagulable disorder 1 3
oronary artery disease 11 38
ardiac arrhythmia 5 17
hronic obstructive
pulmonary disease
5 17
enal insufficiencyb 3 10
uerger’s disease 6 21
utoimmune disorder 7 24
revious bypass 16 55
revious percutaneous
transluminal
angioplasty/stent
6 21
lceration 9 31
edications
Angiotensin-converting
enzyme inhibitor
11 38
Statin 17 59
Acetylsalicylic acid 17 57
Clopidogrel 15 52
Warfarin 10 35
Calcium channel blocker 8 26
Insulin 3 10
Oral antihyperglycemic agent 3 10
Body mass index calculated as weight in kilograms divided by height in
eters squared.
Renal insufficiency defined as (Cr 1.5 mg/dL).as 0.15  0.037 for those limbs enrolled on TBI criteria
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June 20111568 Murphy et al(n  14), and mean baseline ABI was 0.32  0.042 for
those limbs enrolled on ABI criteria (n  16). Seven
patients (24%) did not complete the 1-year assessment of
limb viability due to amputation (2), dropped out of the
study for alternative therapies (3), or death (2).
ABMNC preparation and injection. The average
number of ABMNCs obtained after FC isolation was 1.3
0.7  109 and for the MS isolation was 2.0  1.6  109,
respectively. Cell viability was 97% for both FC and MS.
The ABMNC suspension was concentrated to a volume of
30 mL, and 0.75-mL aliquots were delivered via 40 IM
injections (mean SE 37 6) at 2-cm intervals, 1.5 cm
Fig 1. Bone marrow aspirate is loaded into a closed ste
room (A) and placed into the centrifuge device where th
autologous bone marrow mononuclear cell (ABMNC)
aliquots are delivered via intramuscular (IM) injections a
along the medial and lateral aspect of the index limb (Ddeep into the gastrocnemius muscle, along the medial and rateral aspect of the index limb. In those patients with distal
cclusive disease extending below the malleoli (based on
maging studies prior to enrollment), injections were ex-
ended onto the dorsal and medial foot, in the distribution
f the dorsalis pedal and posterior tibial arteries and termi-
al arcades (Fig 1, A-D).
Safety analysis. There were two procedure-related
AEs. A 71-year-old patient with coronary artery disease
xperienced angina with ST segment depression on an
KG on postprocedure day 1. The patient’s hemoglobin
ad dropped from 11.0 g/dL pre- to 8.8 g/dL post-BM
spiration. The patient was transfused two units of packed
-mL MarrowStim centrifugation tube in the operating
y coat is separated at 1500 rpm for 15 minutes (B). The
uffy coat is aspirated from the tube (C), and 0.75 mL
intervals, 1.5-cm deep into the gastrocnemius muscle,rile 60
e buff
rich b
t 2-cmed blood cells, and the anginal symptoms and EKG
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Volume 53, Number 6 Murphy et al 1569changes resolved without elevation of cardiac enzymes. The
protocol was subsequently modified to decrease the volume
of BM aspirated from 500 to 360 mL to reduce precipitous
shifts in hemoglobin levels in this high cardiac risk popula-
tion. A procedure-related SAE occurred in one patient
during CA of the index limb with entrapment of a guide-
wire in the wall of the common femoral artery, requiring
Fig 2. Change in first toe pressure (FTP), toe-brachial index
(TBI), and ankle-brachial index (ABI) from baseline (mean SE).
FTP increased by 10.2  6.2 mm Hg (P  .02; A) and TBI
increased by 0.10  0.05 (P  .02; B) at week 12 from baseline.
The ABI increased by 0.08  0.04 at week 12 but was not
significant (P  .73; C). ABMNC, Autologous bone marrow
mononuclear cell.open exploration and extraction. There were no wound Aomplications at the BM aspiration site or ABMNC injec-
ion sites in the index limb. Additionally, there were no
dverse events associated with administration of general
nesthesia. There were no serum chemistry or hematologic
bnormalities other than anemia. There were two non-
reatment related deaths in the 1-year follow-up interval, at
weeks and at 8 months.
Amputation-free survival. AFS at 1 year was 86.3%.
here were three amputations during the one-year fol-
ow-up period: day 2, week 5, and week 25 posttreatment.
below-knee amputation (BKA) was performed for severe
schemic rest pain in a 25-year-old male who had a guillo-
ine transmetatarsal amputation for gangrene secondary to
uerger’s disease and IM ABMNC 2 days later. A BKA was
erformed 2 days post-ABMNC treatment for intractable
est pain. A BKA was performed at 5 weeks after ABMNC
njection in a 60-year-old diabetic male who was found to
ave osteomyelitis in the first metatarsal bone of the index
imb that was not discovered on plain X-rays at the time of
creening. An above-knee amputation was performed in an
0-year-old woman with aortoiliac, femoral, and tibial ar-
ery occlusive disease. The baseline ABI of the index limb
as 0.38 and decreased to 0.22 by week 12. There were
wo deaths during the study, at 7 and 26 weeks post-
reatment. The first death occurred in a 55-year-old male
ith ulcerative colitis, rheumatoid arthritis, and insulin-
ependent diabetes mellitus with severe bilateral lower
xtremity ischemia with gangrene (FTP recordings were
bsent in both feet). Despondent over his prognosis, the
atient committed suicide at 7 weeks posttreatment. The
econd death occurred at 26 weeks posttreatment from
omplications 10 days after an above-the-knee amputation
AKA) for gangrene of the index limb, as previously de-
cribed.
Changes in measures of perfusion. There was a sig-
ificant increase from baseline in FTP by 10.2  6.2 mm
g (P .02; Fig 2,A) and in TBI by 0.10 0.05 (P .02;
ig 2, B) at week 12. There was a trend in improvement in
BI at week 12 by 0.08  0.04 (P  .73; Fig 2, C).
able III. Characteristics of responders
Responders: ABI
or TBI 0.15
(n  10)
Non-responders:
ABI or TBI
0.15
(n  20)
ge (years,  SE) 61.7  17.7 67.5  17.2 years
ender (n/%) Female 7/70 Female 8/57
Male 3/30 Male 6/43
aseline ABI ( SE)a 0.18  0.05 0.38  0.04
aseline TBI ( SE)b 0.09  0.04a 0.27  0.05
iabetes (n/%) 4/40 0
ecrease in rest painc 4.2  1.3 cm 2.5  0.8 cm
BI, Ankle-brachial index; TBI, toe-brachial index.
P  .008.
P  .01.
P  .02.pplying recognized clinical thresholds in these hemody-
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June 20111570 Murphy et alnamic indices, we found that 5 of 10 limbs (50%) enrolled
on TBI criteria and 5 of 15 limbs (33%) enrolled on ABI
criteria “responded” to ABMNC treatment by a margin of
0.15 from baseline. There were no significant differences
between the “responder” and “non-responder” groups in
age; however, most responders were female (70%). All four
of the diabetic patients enrolled that completed the 12-
week assessment of perfusion had an increase0.15 in TBI
(3) or ABI (1; Table III). Only one patient had a decrease
in ABI by0.15 at week 12 and eventually had an AKA for
gangrene, as detailed previously. There was an insignificant
increase in TcPO2 at week 12 by 4.1  6.8 mm Hg (P 
.63). The BPI in the treated limb, as quantified by H2O
15
PET-CT perfusion data (Fig 3) increased by 19.3  3.1
from baseline (n  4).
Correlation of cell counts and changes in perfusion.
We found that there was no correlation between total mono-
nuclear cell (MNC) count and changes in ABI (Fig 4, A).
There was a significant difference in counts of KDR cells
between the treatment responders and non-responders; how-
ever, there were no differences in counts of CD34 or
CD133 cells between these two groups (Fig 4, B). It should
be noted that these subpopulations isolated based on
CD34, CD133, and KDR expression represented a small
portion of the total MNC population as compared with
cells expressing the hematopoietic and monocyte marker
CD45 (mean 89.46  3.2%). There was no difference in
the relative composition of CD45 cells between re-
Fig 3. Radiolabeled H2O15 positron emission tomogra
blood perfusion quantified with intra-arterial injection o
(ABMNC) treatment (A) in the left leg and after (B). A B
ratio of H2O
15 peak tracer uptake level of the untreated:
In this patient, the BPI increased from 0.38 at baseline t
ankle-brachial index (ABI) from 0 to 0.32 in the same psponders and non-responders (data not shown). tAdditional efficacy assessments. Rest pain decreased
ignificantly at 12 weeks from baseline with 8 of 15 (53%)
atients enrolled on ABI criteria and 8 of 10 (80%) patients
nrolled on TBI criteria reporting improvement in symp-
oms (Fig 5, A). RP decreased from baseline to a greater
egree in treatment responders than non-responders (Ta-
le III). Within the ABI group, four patients (27%) re-
orted an increase in RP, and within the TBI group, two
atients (20%) reported an increase in RP. Interestingly,
oth of these patients in the TBI group improved by
0.15. The VascuQol total score increased in all catego-
ies, especially in the domains of emotion (2.5  0.3 to
.3  0.5) and pain (2.5  0.4 to 4.0  0.7) (Fig 5, B).
hree of nine ulcers (33%) healed completely by week 12
Fig 6).
ISCUSSION
The report by the TACT investigators was the first
linical assessment of ABMNCs in treating CLI, demon-
trating that IM injection of ABMNCs significantly im-
roved ABI, TcPO2, rest pain, and pain-free walking time
t 24 weeks after treatment.22 Intrigued by these results
nd motivated by a need in our own clinic population, we
sed the TACT report as a template for an open label,
onrandomized Phase I/II clinical trial that was the first
ood and Drug Administration-approved cell-based trial
or PAD in the United States. In the current study, there
ere no deaths within 30 days of treatment. There were
computed tomography scan. A representative image of
O15 before autologous bone marrow mononuclear cell
Perfusion Index (BPI) was calculated by comparing the
d in the segment of the leg denoted by the dashed line.
4 (42%) at 12 weeks, concurrent with an increase in the
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Volume 53, Number 6 Murphy et al 1571ischemia and entrapment of a guidewire during CA. Similar
CLI studies have also reported anemia in patients after large
volume BM aspiration with various adverse events26,31 and
modification of the study protocol prevented further ane-
mia related SAEs. There were no adverse events associated
with administration of general anesthesia, which was a
major concern in this high cardiac risk patient population.
There were two deaths during the 12-month follow-up
period, neither of which was procedure related. The 30-day
perioperative morbidity rate of ABMNC therapy in this
trial, with two SAEs (no deaths) in 30 limbs treated, was
7%. The perioperative morbidity and mortality of lower
extremity amputation ranges from 7% to 17%.1,2,13 Based
on a review of SAEs by an independent data and safety
monitoring board, we conclude that IM administration of
ABMNCs is safe and presents less of a risk to the CLI
Fig 4. Correlation of bone marrow subpopulations and changes
in perfusion. There was no correlation between total mononuclear
cell (MNC) count and changes in ankle-brachial index (ABI)
(R2  0.028; A). Using fluorescent activated cell sorting (FACS)
analysis of endothelial progenitor cell (EPC) surface markers in
ABMNCs we found a significant difference in KDR cells between
responders to treatment as compared to non-responders (1.02 
0.39% vs 0.36  0.12%; P  .008), respectively. There were no
differences in CD34 (4.21 0.80% vs 3.97 0.40%; P .14) or
CD133 (0.59 0.12% vs 0.68 0.17%; P .9) subpopulations
between responders and nonresponders, respectively (B).patient than amputation. pThe second objective of this Phase I/II trial was to assess
he ability of IM injection of ABMNCs to promote AFS, a
omposite of limb salvage and all cause mortality, in patients
ith nooptionCLI.Therewere three amputations during the
2-month follow-up, and, including the two deaths that oc-
urred, the 1-year AFS rate for this study is 86.3%. Similar
tudies have reported AFS rates of 59% to 66.7%.29,30 Our
nthusiasm for the results we report is tempered by the fact
hat this was a nonrandomized, open-label trial, and we ex-
luded patients with a hemoglobin A1c 8.5% and renal
ailure. Thus, the patient population of this trial was not
epresentative of the more morbid CLI population at large.
hen we consider the fate of the contralateral limb of those
atients with bilateral CLI by inclusion criteria (n  12),
lthough less symptomatic with regard to rest pain or tissue
oss, none of the contralateral limbs required amputation
uring the 12-month follow-up. In a larger trial assessing the
ffect of iloprost in patients with CLI, patients randomized to
he placebo armhad a 1-year limb salvage rate of 87%.31 Thus,
ny conclusions regarding efficacy of ABMNC in promoting
FS in CLI will await a larger randomized trial with broader
nclusion criteria.
In the present study we measured FTP, TBI, ABI, and
cPO to assess changes in perfusion of the index limb to
ig 5. Changes in rest pain and quality of life. Using a 10-cm
isual analogue scale, rest pain (RP) significantly decreased at 12
eeks by 2.2  0.6 cm (P  .02; A). The VascuQol total score
ncreased from 2.62 to 4.07 at 12 weeks (P .008) (B).ABMNC,
utologous bone marrow mononuclear cell.2
rovide an objective measure of hemodynamic improve-
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June 20111572 Murphy et alment. We also incorporated ABI and TBI values, in addi-
tion to the clinical findings of rest pain and ulceration, to
more succinctly define CLI for our inclusion criteria as
compared with the broader Fontaine and Rutherford clas-
sifications. Our objective was to provide a more defined
metric by which to quantify response to therapy, consistent
with the recent recommendations by Conte for assessing
responses to intervention in CLI.32 In this study, we found
that 76% of patients had some degree of improvement in
ABI or TBI, and over one-third increased by a clinically
significant margin of 0.15. These results support the
concept that ABMNC improves perfusion in ischemic tis-
sue; however, the exact mechanism by which this occurs
remains to be defined in more elaborate preclinical and
clinical studies. We did find an association between content
of KDR cells in the ABMNC fraction and improvement in
hemodynamic parameters in a small sample population.
This finding will be borne out by current investigations in
our laboratory focusing on BM and peripheral blood de-
rived EPCs from PAD patients in in vitro and in vivo
experiments.
There was a significant improvement in RP with 64%
of patients reporting some degree of improvement from
Fig 6. Ulcer healing. Nine patients with ulceration of th
re-epithelialization was achieved in three patients (33%
46-year-old womanwith Buerger’s disease and an ulcer on
concurrently increased from 2 to 25 mm Hg in this peri
exposed calcaneus bone at baseline (B1) and at 12 week
cover the calcaneus and support a split thickness skin gra
alone, this case is presented to illustrate the potential of
promoting wound healing via enablement of other procbaseline, findings that are consistent with other trials wocusing on cell therapy in the context of CLI.22-25 The
atients enrolled in this open label trial had severe symp-
oms, were highly motivated, and consequently had ex-
ectations for clinical benefit from an unproven thera-
eutic agent, a scenario associated with a 30% to 40%
lacebo effect with a subjective end point such as
P.33-35 Intractable pain is a major indication for lower
xtremity amputation, and consequently it will be imper-
tive to blind patients to treatment in the design of a
hase III efficacy trial that includes major amputation as
component of the end point.
The conduct of this study was modified several times
n response to pitfalls that we encountered. Inclusion of
he sterile centrifugation MS system significantly re-
uced operative time as the ABMNCs were isolated in
he operating room immediately after BM aspiration.
he average procedure time for aspiration, ABMNC
eparation, and cell injection using FC was 527  38.9
inutes and for the MS was 114  18.8 minutes. The
losed MS system did not require gram stains, endotoxin
ssays, and bacterial and fungal cultures necessary to
nsure sterility as with FC. CA was initially incorporated
n the study; however, it required exclusion of patients
x limbwere enrolled. Complete healing of the ulcer with
2 weeks. Representative photographs are shown of a
ight first toe at baseline (A1) and at 12 weeks (A2). FTP
73-year-old male with ulceration of the right heel with
). There was sufficient growth of granulation tissue to
SG). Although not considered a success of trial therapy
logous bone marrow mononuclear cells (ABMNCs) in
s such as STSG.e inde
) at 1
the r
od. A
s (B2
ft (ST
autoith renal insufficiency and provided highly subjective
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MRA for the same purpose as CA. Unfortunately, imag-
ing of vessels of the calf was frequently obscured by
venous contamination and restricted inclusion of pa-
tients with implanted devices, notably pacemakers and
defibrillators, which constituted 20% of our study popu-
lation. Therefore, we eliminated both of these tests and
we developed a novel PET-CT protocol to directly mea-
sure blood volume and perfusion in the treated limb.
This protocol was not standardized at the time of this
report; however, measurements of perfusion correlated
with improvements in ABI. The results for TcPO2 in this
study were widely disparate despite rigorous control of
elements involved in this test, a problem noted by other
investigators as well,36-38 and we will not use this param-
eter as a measure of efficacy in future studies.
In conclusion, this Phase I/II trial has demonstrated
that ABMNC therapy for CLI is safe. In addition, our
results provide compelling evidence suggesting that IM
ABMNC administration promotes AFS survival. Based on
these results, we have moved forward with a pivotal multi-
center randomized, double blinded, Phase III trial, which
will ultimately test the concept that IM ABMNC improves
AFS at 1 year in patients with no option for CLI.
The authors acknowledge Rafat Abonour, MD, and
Nelson, Chao, MD, for assistance with bone marrow aspi-
ration and Pat G’Sell, RN, for assistance in patient recruit-
ment and data collection.
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Supplemental Methods Section
Measures of perfusion. The ankle-brachial index
(ABI) was obtained by measuring the posterior tibial and
dorsalis pedal arteries and the highest brachial artery pres-
sure, and the first digital artery pressure was used for first
toe pressure (FTP) and toe-brachial index (TBI). The FTP,
TBI, and ABI were recorded by the same technician at each
follow-up visit in a temperature controlled room after 15
minutes of rest. TcPO2 measurements were recorded by
means of a sensor placed on the anterior chest wall as a
reference and on the dorsum of the foot for analysis.
Bone marrow aspiration and autologous bone mar-
row mononuclear cell (ABMNC) isolation. In the
prone position and under general anesthesia, bone marrow
(BM; 360-370 mL) was aspirated from the right and left
posterior iliac crests. With the Ficoll density centrifugation
(FC) technique, the patient was recovered from general
anesthesia as the ABMNCs were isolated in the stem cell
laboratory and later returned to the operating room for cell
injection. Using the MarrowStim (MS) centrifuge system,
BM was loaded into the centrifuge tube and the buffy coat
was extracted (Fig 1, A-C). The average number of
ABMNCs obtained for the FC isolation was 1.3  0.7 
109 and for the MS isolation was 2.0  1.6 x 109, respec-
tively. Cell viability was greater than 97% for both FC and
MS. None of the cell preparations were contaminated as
determined by gram stain, bacterial cultures, and endotoxin
assays that were obtained prior to cell administration. The
ABMNC suspension for FS and MS was concentrated to a aolume of 30 mL, and 0.75-mL aliquots were delivered via
M injections at 2-cm intervals, 1.5-cm deep into the
astrocnemius muscle, along the medial and lateral aspect
f the index limb. In those patients with distal occlusive
isease extending below the malleoli (based on imaging
tudies prior to enrollment), injections were extended onto
he dorsal and medial aspects in the distribution of the
orsalis pedal and posterior tibial arteries and terminal
rcades. Injections of ABMNCs (number of injections,
ean 37 6) were delivered starting proximally at the level
f the anterior tibial tuberosity and continued onto the
orsum of the foot (Fig 1, D).
Flow cytometric characterization of endothelial
rogenitor cell subpopulations. Fluorescent activated
ell sorting (FACS) analysis was used to quantify subpopu-
ations of endothelial progenitor cells (EPCs) within the
ononuclear cell (MNC) fraction prior to injection in
ight patients enrolled in the study. Using recognized
urface markers for EPCs,17-19 MNCs were stained with
ifferent primary or isotype control antibodies at 4°C for
0 minutes in 100 L phosphate buffered saline (PBS)
ontaining 2% fetal bovine serum, washed twice with PBS,
xed with 1% paraformaldehyde, and analyzed using a
alibur flow cytometer and Cell QuestPro software (Bec-
on Dickinson Immunocytometry Systems, San Diego,
alif). The following primary antihumanmurinemonoclonal
ntibodies were used (all BD Pharmingen, San Diego, Calif,
nless indicated); CD 133-phycoerythrin (PE), CD 45-
uorescein isothiocyanate (FITC), CD 34-FITC, IgG1-
ITC (isotype control), and IgG1-PE (isotype control),
nd KDR-PE (R & D Systems, Minneapolis, Minn).
